These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16612616)

  • 1. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats.
    Yoshimizu T; Shimazaki T; Ito A; Chaki S
    Psychopharmacology (Berl); 2006 Jul; 186(4):587-93. PubMed ID: 16612616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039.
    Pałucha-Poniewiera A; Wierońska JM; Brański P; Stachowicz K; Chaki S; Pilc A
    Psychopharmacology (Berl); 2010 Dec; 212(4):523-35. PubMed ID: 20703449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.
    Chaki S; Yoshikawa R; Hirota S; Shimazaki T; Maeda M; Kawashima N; Yoshimizu T; Yasuhara A; Sakagami K; Okuyama S; Nakanishi S; Nakazato A
    Neuropharmacology; 2004 Mar; 46(4):457-67. PubMed ID: 14975669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist.
    Karasawa J; Shimazaki T; Kawashima N; Chaki S
    Brain Res; 2005 Apr; 1042(1):92-8. PubMed ID: 15823257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin- and GABA-dependent.
    Stachowicz K; Wierońska J; Domin H; Chaki S; Pilc A
    Pharmacol Rep; 2011; 63(4):880-7. PubMed ID: 22001975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test.
    Shimazaki T; Iijima M; Chaki S
    Eur J Pharmacol; 2004 Oct; 501(1-3):121-5. PubMed ID: 15464070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential.
    Yasuhara A; Nakamura M; Sakagami K; Shimazaki T; Yoshikawa R; Chaki S; Ohta H; Nakazato A
    Bioorg Med Chem; 2006 Jun; 14(12):4193-207. PubMed ID: 16487713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell.
    Karasawa J; Yoshimizu T; Chaki S
    Neurosci Lett; 2006 Jan; 393(2-3):127-30. PubMed ID: 16233956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine.
    Dong C; Zhang JC; Yao W; Ren Q; Ma M; Yang C; Chaki S; Hashimoto K
    Int J Neuropsychopharmacol; 2017 Mar; 20(3):228-236. PubMed ID: 27765808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists.
    Koike H; Iijima M; Chaki S
    Neuropharmacology; 2011 Dec; 61(8):1419-23. PubMed ID: 21903115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors.
    Kawashima N; Karasawa J; Shimazaki T; Chaki S; Okuyama S; Yasuhara A; Nakazato A
    Neurosci Lett; 2005 Apr; 378(3):131-4. PubMed ID: 15781145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats.
    Marek GJ; Salek AA
    J Pharmacol Exp Ther; 2020 Jul; 374(1):200-210. PubMed ID: 32265323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039.
    Yoshimizu T; Chaki S
    Biochem Biophys Res Commun; 2004 Mar; 315(2):493-6. PubMed ID: 14766235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of mgs0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid), a potent metabotropic glutamate receptor antagonist.
    Nakamura M; Kawakita Y; Yasuhara A; Fukasawa Y; Yoshida K; Sakagami K; Nakazato A
    Drug Metab Dispos; 2006 Mar; 34(3):369-74. PubMed ID: 16326817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, in vitro pharmacology, and structure-activity relationships of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as mGluR2 antagonists.
    Yasuhara A; Sakagami K; Yoshikawa R; Chaki S; Nakamura M; Nakazato A
    Bioorg Med Chem; 2006 May; 14(10):3405-20. PubMed ID: 16431115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
    Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
    Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.
    Nakazato A; Kumagai T; Sakagami K; Yoshikawa R; Suzuki Y; Chaki S; Ito H; Taguchi T; Nakanishi S; Okuyama S
    J Med Chem; 2000 Dec; 43(25):4893-909. PubMed ID: 11123999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
    Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
    J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats.
    Shimazaki T; Kaku A; Chaki S
    Eur J Pharmacol; 2007 Dec; 575(1-3):94-7. PubMed ID: 17727837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
    Nakazato A; Sakagami K; Yasuhara A; Ohta H; Yoshikawa R; Itoh M; Nakamura M; Chaki S
    J Med Chem; 2004 Aug; 47(18):4570-87. PubMed ID: 15317467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.